KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.

Neda Rasouli, Ecenur Guder Arslan, Andrei-Mircea Catarig, Kim Houlind, Bernhard Ludvik, Joakim Nordanstig, Harald Sourij, Sebastian Thomas, Subodh Verma, Marc P Bonaca

Diabetes Care 48(9) 1529-1535

PMID40543068
PMCIDPMC12368379
DOI10.2337/dc25-1082
发表日期2025-06-21
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 forest plot;Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图。
摘要

摘要

OBJECTIVE: The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic peripheral artery disease (PAD) and type 2 diabetes. Whether these benefits are consistent across diabetes-related characteristics remains unclear. RESEARCH DESIGN AND METHODS: The primary outcome was the ratio to baseline (ETR) in maximum walking distance (MWD), with pain-free walking distance (PFWD) as a key secondary end point. Both were measured at 52 weeks using a constant load treadmill. Subgroup analyses were performed by diabetes duration, BMI, HbA1c, and diabetes medications. A mixed model for repeated measurements was used, incorporating treatment, region, and subgroup as fixed factors, and baseline value as covariate, along with the treatment-by-subgroup interaction. RESULTS: Among 792 participants (median diabetes duration 12.2 years, HbA1c 7.1%, and BMI 28.7 kg/m2), 35.1% used sodium-glucose cotransporter 2 inhibitors and 31.7% used insulin. Semaglutide significantly improved MWD regardless of diabetes duration (ETR of 1.15 vs. 1.13 for <10 vs. ≥10 years, P = 0.80), BMI (1.12 vs. 1.16 for <30 vs. ≥30 kg/m2, P = 0.58), HbA1c (1.13 for <7% and ≥7%, P = 0.99), or medication use. Semaglutide also improved PFWD across subgroups (P > 0.1 for all interactions). BMI reduction correlated weakly with MWD improvements and was more pronounced in the control individuals with higher baseline BMI. Safety outcomes were consistent across subgroups. CONCLUSIONS: Semaglutide improved walking function in people with PAD and type 2 diabetes, including individuals without obesity and those with well-controlled HbA1c. Benefits were consistent across BMI and HbA1c categories, supporting effectiveness beyond weight or glycemic changes.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1 Changes in MWD and PFWD from baseline to week 52 among STRIDE participants. A : Geometric mean ratio to baseline in MWD by subgroup. B : Mean (±SE) change in MWD from baseline to week 52. C : Geometric mean ratio to baseline in PFWD by subgroup. D : Mean (±SE) change in PFWD from baseline to week 52 by subgroup. FAS, number of participants in full analysis set; N, number of participants contributing to the analysis (defined as number of participants with a nonmissing baseline value and nonmissing factors and having at least one postbaseline measurement of the end point).
非 KM Figure
Figure 2Figure 2 ETR for STRIDE participants. A : MWD stratified by participant type 2 diabetes characteristics in the STRIDE trial. B : PFWD stratified by participant type 2 diabetes characteristics in the STRIDE trial. ETR is presented as ratio of estimated geometric mean ratio to baseline at week 52 of semaglutide 1.0 mg vs. placebo. The solid line at 1 indicates no treatment effect, and the dashed line indicates the main treatment effect estimate of MWD based on the overall cohort of participants who adhered to treatment without initiation of rescue therapy. P interaction denotes unadjusted two-sided P value for test of no treatment by subgroup interaction.
非 KM Figure